GSK's (GSK) once-daily lung drug LAMA/LABA performed well in late-stage testing in patients with...

|By:, SA News Editor

GSK's (GSK) once-daily lung drug LAMA/LABA performed well in late-stage testing in patients with chronic obstructive pulmonary disease. GSK, which plans to begin filing for regulatory approval at the end of the year, hopes LAMA/LABA will be a successor to Advair. GSK is developing the drug with Theravance (THRX), whose shares are +8%.